ALFA FinderBSE filing, NSE: SENORES. Summary written from the filing by ALFA Finder's alert engine.
Senores Pharmaceuticals Ltd: key numbers
- Share price
- ₹1,175.00
- Market cap
- ₹5,411 Cr
- Revenue (annual)
- ₹632.6 Cr
- Net profit (annual)
- ₹115.4 Cr
- P/E (TTM)
- 40.5×Sector 43.4×
- Promoter holding
- 45.82%+0.00% QoQ
- FII holding
- 6.01%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Senores Pharmaceuticals Ltd
All →Senores Pharmaceuticals Earnings Call Transcript: Key Takeaways
Senores delivered record quarterly revenue and EBITDA, driven by US portfolio expansion and regulated market growth.
- Call
- Guides 40% growth
Senores Pharmaceuticals Other Announcement
Senores Pharmaceuticals reported no deviation in utilising the Rs 95 Crore raised via a preferential warrant issue for the quarter ended September 30, 2026. Audit Committee reviewed the statement and the Board took it on record.
- Value
- ₹95.00 Cr
Senores Pharmaceuticals Capacity Expansion: ₹20 Cr Investment
Senores Pharmaceuticals' subsidiary Apnar Pharma Private Limited plans a 0.7 Bn unit capacity addition by March 2027. The investment is Rs.20.00 Crore, funded by internal accruals and IPO proceeds.
- Value
- ₹20.00 Cr
- Execution
- By end of March 2027
- production capacity
- 0.7 Bn units
Senores Pharmaceuticals Capacity Expansion: ₹18 Cr Investment
Senores Pharmaceuticals plans to add 0.8 Bn units of capacity to its existing 1.2 Bn unit plant by March 2027. The investment is Rs.18.00 Crore, funded by internal accruals and IPO proceeds.
- Value
- ₹18.00 Cr
- Execution
- By end of March 2027
- production capacity
- 0.8 Bn units
Senores Pharmaceuticals Other Announcement
Senores Pharmaceuticals appointed Talati and Talati LLP as Statutory Auditor for a 60-month term, effective 29 October 2026. The appointment was approved at the board meeting held the same day.
- Execution
- 60 months
Senores Pharmaceuticals Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹192.3 Cr (+24.9%), EBITDA ₹57.7 Cr (+38.3%, 30.0% margin), PAT ₹36.6 Cr. H1 revenue +30%, EBITDA +58.2%.
Other annual report announcements
All →Generic Engineering Construction and Projects Annual Report
Generic Engineering filed its FY2025-26 Annual Report ahead of its 32nd AGM on 30 November 2026. The filing covers board changes and a planned bank-funded EPC expansion.
Vineet Laboratories Annual Report
Vineet Laboratories filed its FY 2025-26 Annual Report, which marks its turnaround and recapitalisation year. The AGM is scheduled for 30 November 2026.
Indrayani Biotech Annual Report
Indrayani Biotech has filed its 34th Annual Report for FY2025-26, containing the AGM notice for 30 November 2026 by VC/OAVM. The chairman notes a Rights Issue was initiated in October 2026 to raise capital.
ESDS Software Solution Annual Report
ESDS Software Solution submitted its FY2025-26 Annual Report along with the AGM notice. The AGM is on 30 November 2026 via VC/OAVM, with remote e-voting.
The Orissa Minerals Development Company Annual Report
Orissa Minerals Development Company filed its FY 2025-26 Annual Report and 108th AGM notice, with the AGM set for 30 November 2026. The filing is a Regulation 34 intimation with no transaction or financial event.
Viksit Engineering Annual Report
Viksit Engineering filed its 44th Annual Report for FY 2025-26 with BSE. The report includes notice of the AGM on 30 November 2026.